Compare KraneShares CSI China Internet ETF (KWEB) vs Medpace Holdings Inc (MEDP) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
KraneShares CSI China Internet ETF vs Medpace Holdings Inc — how do they compare? KraneShares CSI China Internet ETF trades at $27.57, while Medpace Holdings Inc trades at $599.87 (market cap $16.90B). The key difference: Medpace Holdings Inc is trading nearer its 52-week high, KraneShares CSI China Internet ETF nearer its low. Which is the better fit depends on your goals.
| KWEB | MEDP | |
|---|---|---|
Sector | Sector/Thematic | Technology |
52-Week High | $42.94 | $620.59 |
52-Week Low | $23.63 | $393.42 |
Market Cap | — | $16.90B |
Enterprise Value | — | $16.52B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
KWEB trades at $27.525, down 5.48% today amid pressure on Chinese stocks. The technical outlook is bullish with moving averages supporting an uptrend, while oscillators are neutral. Recent news highlights institutional buying and China's strong export growth, though regulatory risks persist.
The ETF offers exposure to China's internet and AI sectors, trading near 52-week lows with potential for rebound driven by AI growth and government support. Key risks include U.S.-China tensions and domestic economic volatility, requiring careful risk assessment for investors.
MEDP trades at $600.00, down 0.4% on the day, with a bullish technical signal driven by moving averages. The company reported strong Q2 2026 earnings, beating estimates with EPS of $4.25, and raised full-year guidance. Revenue growth is robust, with 2026 projected at $2.8 billion, though valuation multiples like a P/E of 35.58 and P/B of 38.95 are elevated. Net cash flow is expected to turn positive in 2026, and institutional activity is mixed, with some funds increasing stakes while others trim positions.
Outlook is positive due to earnings momentum and record bookings, but risks include high valuation sensitivity and a shareholder lawsuit investigation. Analyst consensus is a $599.57 price target with a 'Hold' bias, suggesting limited near-term upside from current levels amid growth-priced expectations.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About KraneShares CSI China Internet ETF
KWEB tracks the CSI Overseas China Internet Index, providing exposure to Chinese software and services companies listed in the US and Hong Kong, including giants like Tencent, Alibaba, and Meituan.
Read more on KWEB →About Medpace Holdings Inc
Medpace Holdings, Inc. is a full-service clinical contract research organization (CRO) that provides comprehensive and scientifically-driven clinical development services to the biotechnology, pharmaceutical, and medical device industries. The company specializes in conducting global clinical trials for new drug and medical device approvals. Medpace's model emphasizes therapeutic expertise and a highly integrated approach to accelerate the clinical development process for its clients.
Read more on MEDP →
